Friday, 15 Nov 2019

You are here

Checkpoint Inhibitor-related Myositis – Something Different

As expected, this year’s ACR meeting saw an upswing in the number of abstracts on immune related adverse events from checkpoint inhibitor therapy compared to last year. With the increase in approved indications for checkpoint inhibitors (CPIs), rheumatologists everywhere are going to be getting referrals for rheumatic irAEs.

Two abstracts in particular caught my eye as they both shed some light on CPI-related myositis, a rare but often devastating complication.

Andrew Mammen presented results of a study (abstract #2288) in which they collected serum and PBMCs before and after avelumab (anti-PD-L1) therapy in patients with thymoma and monitored for CK elevations. They also assessed for thymoma- and myositis-associated autoantibodies. They enrolled 8 patients, all with normal baseline CK levels. Four patients developed elevated CK (762-16,037 IU/L) and proximal muscle weakness after avelumab initiation. These patients were treated with immunosuppressive therapy for myositis and all CK levels normalized within weeks. Of note, one patient with myositis also developed myocarditis. Very interestingly, all 4 patients who developed myositis had pre-existing anti-AChR autoantibodies, and none were positive for any traditional myositis autoantibody. While we are still learning the pathophysiologic mechanism of irAEs, this study suggests that some patients who develop myositis may have a predisposition to autoimmunity, and that we should be screening these patients pre-CPI.

A second abstract (#2976) looking at 180 CPI-related myositis cases collected from a WHO database (VigiBase) found that this entity carries a significant morbidity and mortality, with fatalities occurring 21.2%. They also found a proportion of patients have atypical features including concurrent myocarditis in 16.1% and myasthenia gravis-like symptoms in 15.6%.

We have much to learn about rheumatic irAEs, and the 20+ abstracts presented at this meeting reassure me we are headed in the right direction to answering key questions about risk factors, biomarkers, pathophysiology and treatment, as well as raising awareness among rheumatologists.


Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.